Jallal Bahija 4

4 · Immunocore Holdings plc · Filed Feb 19, 2026

AI-generated summary of this filing

Updated Feb 19, 2026

Immunocore (IMCR) CEO Jallal Bahija Sells Shares, Receives RSU Awards

What Happened

Jallal Bahija, CEO of Immunocore Holdings plc (IMCR), reported several transactions dated Feb 17–18, 2026. He sold 11,474 shares in an open-market sell-to-cover transaction for a weighted average price of $32.35, generating proceeds of $371,184.
On Feb 17, 2026, Bahija also reported conversions/exercises of 23,817 derivative shares (reported at $0) and grant awards totaling 483,639 RSUs/derivative shares (88,573 and 395,066) reported at $0. The filings show both acquisitions (awards/conversions) and a small sale to cover tax liabilities.

Key Details

Transaction dates: conversions/grants dated Feb 17, 2026; market sale dated Feb 18, 2026. Form filed Feb 19, 2026.
Sale details: 11,474 shares sold at a weighted average $32.35 (range reported $32.17–$32.70); total reported proceeds $371,184. Reporting person can provide breakdown by price on request.
Awards/conversions: 88,573 RSUs and 395,066 RSUs granted (each RSU = right to one Ordinary Share); 23,817 derivative shares exercised/converted (reported $0 in column 4).
Tax withholding: sale was pursuant to a sell-to-cover to satisfy income tax liabilities on RSU vesting (footnote).
ADS note: Ordinary Shares may be represented by American Depositary Shares (each ADS = one Ordinary Share).
Vesting/award schedules (from footnotes): some RSUs/options vest in installments beginning in 2026–2027 (see filing footnotes for exact schedules).
Holdings after transaction: the Form 4 did not disclose an aggregate post-transaction total in this summary.
Timeliness: Form 4 was filed two days after the primary transactions (filed Feb 19 for transactions through Feb 17–18); no late filing flag noted.

Context

The sale appears to be a routine sell-to-cover to satisfy tax withholding on RSU vesting rather than a large discretionary sell; such sales are common after awards vest.
The derivative transactions indicate exercises/conversions and award grants; when derivative shares are immediately sold to cover taxes or costs, that is effectively a cashless-type outcome.
These filings are factual disclosures of insider activity and do not, by themselves, indicate the insider’s future view of the company.

Form 4

Period: 2026-02-17

DirectorCHIEF EXECUTIVE OFFICER

Transactions

Exercise/Conversion
Ordinary Shares
[F1]
2026-02-17+23,817→ 23,817 total
Sale
Ordinary Shares
[F1][F2][F3]
2026-02-18$32.35/sh−11,474$371,184→ 12,343 total
Exercise/Conversion
Restricted Share Units
[F4][F5][F1]
2026-02-17−23,817→ 71,453 total
→ Ordinary Shares (23,817 underlying)
Award
Restricted Share Units
[F4][F6][F1]
2026-02-17+88,573→ 88,573 total
→ Ordinary Shares (88,573 underlying)
Award
Employee Share Option (Right to Buy)
[F7][F1]
2026-02-17+395,066→ 395,066 total
Exercise: $32.38Exp: 2036-02-16→ Ordinary Shares (395,066 underlying)

Footnotes (7)

[F1]Ordinary Shares may be represented by American Depositary Shares. Each American Depositary Share represents one Ordinary Share.
[F2]The shares were sold pursuant to a sell-to-cover arrangement for the purpose of satisfying income tax liabilities incurred upon vesting of restricted share units ("RSUs").
[F3]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $32.17 to $32.70 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
[F4]Each RSU represents a contingent right to receive one Ordinary Share.
[F5]On February 17, 2025, the Reporting Person was granted 95,270 RSUs, vesting in four equal annual installments beginning February 17, 2026, subject to the Reporting Person's continuous service through each such vesting date.
[F6]The RSUs vest in four equal annual installments beginning February 17, 2027, subject to the Reporting Person's continuous service through each such vesting date.
[F7]25% of the shares subject to the option award shall vest on February 17, 2027, and 6.25% of the shares subject to the option award shall vest in quarterly installments thereafter, subject to the Reporting Person's continuous service through each such vesting date.

Signature

/s/ Lily Hepworth, Attorney-in-Fact|2026-02-19

1 file